Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HeartMate II PMA

This article was originally published in The Gray Sheet

Executive Summary

Thoratec amends PMA filing for its HeartMate II left-ventricular assist device as a bridge to cardiac transplant in response to an FDA letter outlining deficiencies, the firm announces July 31. The amended filing includes new data from 279 patients, including 194 patients who have reached the 180-day pivotal study endpoint. The original PMA, filed last winter, included data from 133 patients. Following a May meeting with FDA, Thoratec revised its expectation for approval to late 2007 or early 2008 (1"The Gray Sheet" May 7, 2007, p. 13). The company also has enrolled 377 patients in a trial intended to establish HeartMate II as a "destination therapy"...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel